Clinical Trial Update: A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of CC-96673 in relapsed or refractory Non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CC-96673

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: TERMINATED